The Zollinger-Ellison syndrome: is there a role for somatostatin analogues in the treatment of the gastrinoma?
Purpose Analyze the role of somatostatin analogues (SSAs) in the treatment of sporadic and MEN1-related gastrinomas, trying to define whether recent trials have changed the landscape of gastrinoma therapy.
Methods We evaluate the rationale of SSA use in the treatment of gastrinomas, summarize the current literature concerning the effect of SSAs on the control of Zollinger- Ellison syndrome (ZES) and gastrinomas tumor progression and discuss their role in the most recent guidelines.